Clinical Trials | January 12, 2026
Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The company previously completed a $150 million venture investment, acquisition, and recapitalization
The approval is supported by data from three pivotal clinical trials
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
Subscribe To Our Newsletter & Stay Updated
